Unicycive Therapeutics Stock Forecast

Buy candidate since Jun 22, 2026 Gain 1.91%

The Unicycive Therapeutics, Inc. stock price gained 1.91% on the last trading day (Tuesday, 23rd Jun 2026), rising from $7.87 to $8.02. During the last trading day the stock fluctuated 9.33% from a day low at $7.72 to a day high of $8.44. The price has risen in 5 of the last 10 days and is up by 20.42% over the past 2 weeks. Volume fell on the last day by -939 thousand shares and in total, 2 million shares were bought and sold for approximately $13.89 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 11.15% during the next 3 months and, with a 90% probability hold a price between $7.56 and $9.93 at the end of this 3-month period.

UNCY Signals & Forecast

Mostly positive signals in the chart today. The Unicycive Therapeutics, Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at $7.33 and $7.61. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Monday, June 08, 2026, and so far it has risen 20.42%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.

Support, Risk & Stop-loss for Unicycive Therapeutics, Inc. stock

Unicycive Therapeutics, Inc. finds support from accumulated volume at $7.87 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.720 between high and low, or 9.33%. For the last week, the stock has had daily average volatility of 10.17%.

Our recommended stop-loss: $7.75 (-3.32%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 10 days ago.)

Trading Expectations (UNCY) For The Upcoming Trading Day Of Wednesday 24th

For the upcoming trading day on Wednesday, 24th we expect Unicycive Therapeutics, Inc. to open at $8.06, and during the day (based on 14 day Average True Range), to move between $7.71 and $8.33, which gives a possible trading interval of +/-$0.610 (+/-7.91%) up or down from last closing price. If Unicycive Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 7.91% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $8.08 (0.75%) than the support at $7.87 (1.87%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Unicycive Therapeutics, Inc. stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Unicycive Therapeutics, Inc. stock to perform well in the short-term.

Current score: 4.341 Buy Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 24, 2026 - $8.06 ( 0.457%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk